BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30275228)

  • 1. Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial.
    Shinkai M; Imano M; Chiba Y; Hiraki Y; Kato H; Iwama M; Shiraishi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
    Anticancer Res; 2018 Oct; 38(10):5975-5981. PubMed ID: 30275228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
    Shinkai M; Imano M; Chiba Y; Hiraki Y; Kato H; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
    Anticancer Res; 2018 Oct; 38(10):5969-5974. PubMed ID: 30275227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
    Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
    J Surg Oncol; 2019 Jan; 119(1):56-63. PubMed ID: 30444009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
    Yamaguchi H; Kitayama J; Ishigami H; Emoto S; Yamashita H; Watanabe T
    Cancer; 2013 Sep; 119(18):3354-8. PubMed ID: 23798046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
    Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
    Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial.
    Kodera Y; Takahashi N; Yoshikawa T; Takiguchi N; Fujitani K; Ito Y; Miyamoto K; Takayama O; Imano M; Kobayashi D; Miyashita Y; Morita S; Sakamoto J
    Gastric Cancer; 2017 Jan; 20(1):190-199. PubMed ID: 26879545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings.
    Ishigami H; Yamaguchi H; Yamashita H; Asakage M; Kitayama J
    Gastric Cancer; 2017 Mar; 20(Suppl 1):128-134. PubMed ID: 28028665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
    Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Okada K; Mori M; Doki Y
    Ann Surg Oncol; 2011 Dec; 18(13):3726-31. PubMed ID: 21584835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
    Kobayashi D; Ishigami H; Kanda M; Tanaka C; Yamaguchi H; Kitayama J; Kodera Y
    Oncology; 2020; 98(1):48-52. PubMed ID: 31487733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
    Kitayama J; Ishigami H; Yamaguchi H; Yamashita H; Emoto S; Kaisaki S; Watanabe T
    Ann Surg Oncol; 2014 Feb; 21(2):539-46. PubMed ID: 23975319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer.
    Tamura S; Miki H; Okada K; Miyake T; Yoshimura M; Suzuki R; Nakahira S; Nakata K; Okamura S; Sugimoto K; Takatsuka Y
    Int J Clin Oncol; 2008 Dec; 13(6):536-40. PubMed ID: 19093182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
    Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
    Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis.
    Ishigami H; Kitayama J; Kaisaki S; Yamaguchi H; Yamashita H; Emoto S; Nagawa H
    Oncology; 2010; 79(3-4):269-72. PubMed ID: 21372602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
    Ishigami H; Kitayama J; Kaisaki S; Hidemura A; Kato M; Otani K; Kamei T; Soma D; Miyato H; Yamashita H; Nagawa H
    Ann Oncol; 2010 Jan; 21(1):67-70. PubMed ID: 19605503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial.
    Ishigami H; Fujiwara Y; Fukushima R; Nashimoto A; Yabusaki H; Imano M; Imamoto H; Kodera Y; Uenosono Y; Amagai K; Kadowaki S; Miwa H; Yamaguchi H; Yamaguchi T; Miyaji T; Kitayama J
    J Clin Oncol; 2018 Jul; 36(19):1922-1929. PubMed ID: 29746229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis.
    Yamaguchi H; Satoh Y; Ishigami H; Kurihara M; Yatomi Y; Kitayama J
    Ann Surg Oncol; 2017 Oct; 24(11):3345-3352. PubMed ID: 28726078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination Chemotherapy Including Intraperitoneal(IP)Administration of Paclitaxel(PTX)followed by PTX, CDDP and S-1Triplet Chemotherapy for CY1P0 Gastric Cancer].
    Shinkai M; Imano M; Hiraki Y; Kato H; Iwama M; Shiraishi O; Yasuda A; Kimura Y; Imamoto H; Furukawa H; Yasuda T
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1355-1357. PubMed ID: 29394632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis.
    Imano M; Yasuda A; Itoh T; Satou T; Peng YF; Kato H; Shinkai M; Tsubaki M; Chiba Y; Yasuda T; Imamoto H; Nishida S; Takeyama Y; Okuno K; Furukawa H; Shiozaki H
    J Gastrointest Surg; 2012 Dec; 16(12):2190-6. PubMed ID: 23099736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination.
    Okabe H; Ueda S; Obama K; Hosogi H; Sakai Y
    Ann Surg Oncol; 2009 Dec; 16(12):3227-36. PubMed ID: 19777180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential S-1 plus intravenous paclitaxel for serosa-positive gastric cancer.
    Peng YF; Imano M; Itoh T; Satoh T; Chiba Y; Imamoto H; Tsubaki M; Nishida S; Yasuda T; Furukawa H
    J Surg Oncol; 2015 Jun; 111(8):1041-6. PubMed ID: 26060133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.